ArticleMedicine2025
Probing the association between PD-1/PD-L1 expression and atrial fibrillation in peripheral blood of Han and Kazakh populations in Xinjiang region.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the association between peripheral blood programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) expression and atrial fibrillation (AF) in the Han and Kazakh populations of Xinjiang. From May 2017 to December 2018, the Han and Kazakh groups in Xinjiang were selected for analysis using flow cytometry and other methodologies. Rigorous quality control measures were implemented to assess indicators associated with AF. Research has demonstrated that among the Han Kazakh group with AF, the positive expression rate of PD-1/PD-L1 on CD4+ T lymphocytes and dendritic cells in the AF cohort is lower than that observed in the control group, indicating a significant difference between the 2 ethnic groups. Additionally, the proliferation capacity of lymphocytes and the levels of cytokine secretion also exhibit differences that can be mitigated or reversed through treatment with interferon-α. Notably, the proliferation ability of the Han population is greater than that of the Kazakh population. Significant differences exist in the immune cell and cytokine profiles, as well as in PD-1/PD-L1 expression, between the Han and Kazakh groups with AF in Xinjiang and the control group. These differences may present potential targets for the treatment of AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.